Study on Dupilumab for Treating Metastatic Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria

• Must have a confirmed diagnosis of non-small cell lung cancer (NSCLC).
• Cancer must have progressed after previous treatment with PD-1 or PD-L1 targeted therapy.
• Can have had only one or no other treatments since the last PD-(L)1 therapy.
• Must be willing to provide blood samples and undergo tumor biopsies as part of the study.
• Must be 18 years or older.
• Must have an ECOG performance status of 0 to 2, unless a long-term disability is present that does not affect response to therapy.
• Women of childbearing potential and men must agree to use effective contraception during the study and for three months after treatment.
• Must be able to understand and sign a consent form.

Exclusion Criteria

• Cannot have had chemotherapy within 14 days before starting the study treatment.
• Palliative radiotherapy is allowed if it is in the patient's best interest.
• Cannot have uncontrolled illnesses, such as ongoing infections, heart failure, or unstable mental health conditions.
• Cannot be pregnant or nursing due to potential risks to the baby.
• Cannot have an immune deficiency or be on immunosuppressive therapy within seven days before starting the study treatment, except for stable low-dose steroids.
• Cannot have active autoimmune diseases requiring treatment in the past year, except for replacement therapies like insulin.
• Cannot have conditions or treatments that might interfere with the study or are not in the patient's best interest.
• Cannot have HIV with a detectable viral load or unstable treatment.
• Cannot have active Hepatitis B or C infections, unless controlled with treatment.
• Cannot have had a bone marrow or organ transplant.
• Cannot have received a live vaccine within 30 days before starting the study.
• Cannot have allergies to protein-based treatments.
• Cannot have unresolved immune-related side effects from previous immunotherapy.
• Cannot have a history of lung diseases like interstitial lung disease or pneumonitis from previous cancer treatments.